We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

1 hedge funds and large institutions have $2.28M invested in Hepion Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% less funds holding

Funds holding: 3 → 1 (-2)

69% less capital invested

Capital invested by funds: $7.45M → $2.28M (-$5.17M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
1
Holders Change
-2
Holders Change %
-66.67%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
EI
EAM Investors
California
-$3.11M
2
TCIM
TIAA CREF Investment Management
New York
-$2.08M
3
HighTower Advisors
HighTower Advisors
Illinois
-$27K
4
VKH
Virtu KCG Holdings
New York
-$22K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.15M – – –
Morgan Stanley
2
Morgan Stanley
New York
$392K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$178K – – –
PFS
4
Prospera Financial Services
Texas
$140K – – –
SIM
5
Spark Investment Management
New York
$139K – – –
BFA
6
BlackRock Fund Advisors
California
$98K – – –
Bank of New York Mellon
7
Bank of New York Mellon
New York
$43K – – –
Cambridge Investment Research Advisors
8
Cambridge Investment Research Advisors
Iowa
$42K – – –
Northern Trust
9
Northern Trust
Illinois
$26K – – –
BIT
10
BlackRock Institutional Trust
California
$17K – – –
Bank of Montreal
11
Bank of Montreal
Ontario, Canada
$15K – – –
UBS Group
12
UBS Group
Switzerland
$10K – – –
BA
13
BlackRock Advisors
Delaware
$8K – – –
BIM
14
BlackRock Investment Management
Delaware
$6K – – –
Wells Fargo
15
Wells Fargo
California
$5K – – –
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
$4K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$3K – – –
S
18
SignatureFD
Georgia
$2K – – –
VIA
19
Vantage Investment Advisors
Pennsylvania
$2K – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$1K – – –
EI
21
EAM Investors
California
– -$3.11M -1 Closed
TCIM
22
TIAA CREF Investment Management
New York
– -$2.08M -1 Closed
HighTower Advisors
23
HighTower Advisors
Illinois
– -$27K – –
VKH
24
Virtu KCG Holdings
New York
– -$22K – –

HEPA Hedge Fund Activity: Q4 2015 in Review

1 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2015, worth a combined $2.28M — down 69% from $7.45M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of HEPA and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was EAM Investors, exiting entirely with an estimated $3.11M sold.

  • 1 institutional investor held Hepion Pharmaceuticals (HEPA) as of Q4 2015, down from 3 in Q3 2015.
  • Funds reported $2.28M of Hepion Pharmaceuticals stock for Q4 2015, down 69% quarter-over-quarter.
  • 0 funds opened new Hepion Pharmaceuticals positions in Q4 2015 and 2 closed out, a net change of -2 holders.
  • The largest Hepion Pharmaceuticals seller in Q4 2015 was EAM Investors, an estimated $3.11M sold.

Based on aggregated 13F filings for Q4 2015.